You just read:

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

News provided by

Astellas Pharma US, Inc.

Sep 24, 2018, 09:00 ET